{"name":"Ocuphire Pharma, Inc.","slug":"ocuphire-pharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":5476776,"netIncome":-49591000,"cash":45091000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Low dose pilocarpine","genericName":"Low dose pilocarpine","slug":"low-dose-pilocarpine","indication":"Open-angle glaucoma","status":"phase_3"},{"name":"Phentolamine Opthalmic Solution 0.75%","genericName":"Phentolamine Opthalmic Solution 0.75%","slug":"phentolamine-opthalmic-solution-0-75","indication":"Presbyopia (age-related loss of accommodation)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Phentolamine Mesylate Ophthalmic Solution 1%","genericName":"Phentolamine Mesylate Ophthalmic Solution 1%","slug":"phentolamine-mesylate-ophthalmic-solution-1","indication":"Other","status":"phase_2"},{"name":"Phentolamine Ophthalmic Solution 0.75%","genericName":"Phentolamine Ophthalmic Solution 0.75%","slug":"phentolamine-ophthalmic-solution-0-75","indication":"Presbyopia (age-related loss of accommodation)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APX3330","genericName":"APX3330","slug":"apx3330","indication":"Treatment of diabetic retinopathy","status":"phase_2"}]}],"pipeline":[{"name":"APX3330","genericName":"APX3330","slug":"apx3330","phase":"phase_2","mechanism":"Inhibits the enzyme TGFBR2","indications":["Treatment of diabetic retinopathy"],"catalyst":""},{"name":"Low dose pilocarpine","genericName":"Low dose pilocarpine","slug":"low-dose-pilocarpine","phase":"phase_3","mechanism":"Low-dose pilocarpine is a muscarinic acetylcholine receptor agonist that stimulates parasympathetic activity to increase aqueous humor outflow and reduce intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Phentolamine Mesylate Ophthalmic Solution 1%","genericName":"Phentolamine Mesylate Ophthalmic Solution 1%","slug":"phentolamine-mesylate-ophthalmic-solution-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Phentolamine Ophthalmic Solution 0.75%","genericName":"Phentolamine Ophthalmic Solution 0.75%","slug":"phentolamine-ophthalmic-solution-0-75","phase":"phase_3","mechanism":"Phentolamine is an alpha-adrenergic antagonist that blocks norepinephrine signaling in the eye to reduce pupil dilation and improve visual function in patients with presbyopia.","indications":["Presbyopia (age-related loss of accommodation)"],"catalyst":""},{"name":"Phentolamine Opthalmic Solution 0.75%","genericName":"Phentolamine Opthalmic Solution 0.75%","slug":"phentolamine-opthalmic-solution-0-75","phase":"phase_3","mechanism":"Phentolamine is an alpha-adrenergic receptor antagonist that blocks norepinephrine signaling in the eye to reduce pupil dilation and improve aqueous humor outflow.","indications":["Presbyopia (age-related loss of accommodation)","Intraocular pressure reduction in glaucoma or ocular hypertension (investigational)"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1XaHBmTDdGandMWC1vN1kxUUdjZnpIS1hodnFwTXVjSzFVYWM4dXE0XzlRdms5Yi13UWRoTGVLWWNGME9MSmVWMmdIMElIWUlmVy1XQ0dtZXI1RXdPTmp0YkRBVG5aQQ?oc=5","date":"2026-03-21","type":"pipeline","source":"Stock Titan","summary":"OCUP SEC Filings - Ocuphire Pharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"OCUP SEC Filings - Ocuphire Pharma Inc 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQajVTaXBWVU9mUmtrXzQ4TXhFSzFlUnJYaHdSa2JEQ0xkb1k4UmFlaTlYQmktSTJjSWd5aGlIYlcyX3JvX0otNHpKMDJkTWxjS2hNbFN2cENBT0tIR3N3ZWc2Z2RCdWotX21Sa2pONlB2bXNRRW9WY3BMTHprRmFoSFBrWnhNRU9uR2dsQXJNQ3ZndUFWcTlXcHBITldFOFRmaXI1MVdXX3JMbl84aS0wODNWN28tVzVHck1iMjhpTjd6Zw?oc=5","date":"2026-03-12","type":"pipeline","source":"Markets Mojo","summary":"Ocuphire Pharma Hits New 52-Week High of $5.30, Up 185% Year-Over-Year - Markets Mojo","headline":"Ocuphire Pharma Hits New 52-Week High of $5.30, Up 185% Year-Over-Year","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQRFJJTmFIdC1QUmFrdGFwUDdIcklYdzVaOHBqWDRiakRnbEJLc0VVblVPazRIZENZZ3paQ2lpLWJRMVJpRWttMlZaRHJZRDNnNV9lUXZTTm83MHVQbF9ZQTd4dlhzdDBRd2w2aExOU0xfeDJ4TmFuR1Jsd0J5QXVlX3VaTzlTanhnTURrR2I3OEtNdzI3R1plTjNvb1VZTGFELXZEemZTSzZzWGF0V3ZDUg?oc=5","date":"2026-03-10","type":"pipeline","source":"Markets Mojo","summary":"Ocuphire Pharma Hits New 52-Week High of $5.10, Up 180.59% - Markets Mojo","headline":"Ocuphire Pharma Hits New 52-Week High of $5.10, Up 180.59%","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5VZ3BXZ0R0eFJDTHdzb0dtbi1kVWZla2ZGdDcwZFh1Q1FESWVieTVhOHNDWEdlNzMtZTNSdGRHY2RCNl90SXMzVVZaT0lBZmp2MmFJ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"OCUP Stock Price, News & Analysis - Stock Titan","headline":"OCUP Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxORDNGWG1JWFFxYUVLUmRHN09Ndm5ra2JFQXRxSVdveFdfZGFvMnc3bXBkczhBbHIzWjU0OVcwazk2cFdjUm9pR3B6WWxPVnNZWi1hWjR4TEtVeVNwNVZESHV6am82eTcwaWRaVVkxVkhWSmhjUk1qZS1WMk5IUERVbkpBWjVrN243WHBiZ0k0SXZuNFdhWllUV0dLSmgtTHhIZXNJbXNGbjdmOFRvMzV4em1Zel9lejN1OWZEZGtCOXM?oc=5","date":"2024-10-25","type":"pipeline","source":"PR Newswire","summary":"The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - PR Newswire","headline":"The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQMmtsRWcwTGxEWjBMeDV4M3RPNVdleWdKZnFkS3B2MlM4V1lxQ09SaDJmOGdQWXplWTRzRURFVWhUNGtHTE9mM2JaTUN1TjVjOVI1d3A2V2Nhc0lNYXlQdTc1NlpTS09OcDI3RVZ1SU9JcXdZVXo3U2pFY25PNGw3VU5tMGlXWVNYVXhnMUNIRDI0b2lhOV9sYmdJODBNdw?oc=5","date":"2024-10-23","type":"deal","source":"Yahoo Finance","summary":"Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal - Yahoo Finance","headline":"Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPZERndFpCSExmMUhjMUREWkZoMW11TU9RdUVlRkxSdFJ0SXVmbmRTbnBfSWFQQmRra3VpWGdfR2lOdkY0SzFyRnB5R2ZxTzdRYVJCWm9QNDVhdUtBaU5wcDFaX2JiVEg5bExaRkJSNW50M1poVTFOTWRid3JXSDJsdXdtS3hCQVVUMWNqQ0FjUjJHcTJFOVc4YWJyYUNSdGx0UkJLLQ?oc=5","date":"2024-10-23","type":"pipeline","source":"Fierce Biotech","summary":"Ocuphire Pharma to transform into gene-therapy-focused biotech via Opus acquisition - Fierce Biotech","headline":"Ocuphire Pharma to transform into gene-therapy-focused biotech via Opus acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxONlBUZWswaHZ4S1UtWGQxdi1hQXZKU2xXSzc3OXRSR0EtOEdEel9CdGdsZ0V5VFlERXVnNEozcVZlM2FfNW9KbDN2Nm9VcHF4MDdkMGdaWHJ3WDFsT3NpelVnRGV2d196VXp1X2NyX2szYkhybVFxY092OWp3bkJUYWM4OWpJcVBLamc?oc=5","date":"2024-10-23","type":"pipeline","source":"Yahoo Finance","summary":"Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance","headline":"Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE05VmpGQnZyNUhOTzFXQ3JfQnQ4NWMtOFlNUWxia1VFOW9PYWNENGs4dFBrWkVrcl9IYmtTY0xXanFOZjhiUWtoREt2TEJsYmtIdjhSalozcDh2eFFXNFNuM3BmcHQ2WkE0VkJORjBfbHFzQmpMQ01HdDFqVkE?oc=5","date":"2024-10-22","type":"deal","source":"Modern Retina","summary":"Ocuphire Pharma acquires Opus Genetics - Modern Retina","headline":"Ocuphire Pharma acquires Opus Genetics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQakhMdk9nbjJTTUZoNWgwam5jWkV3eFJSVGQ3SnpKMzFTekRRMk12R0Y2azl2amRPbFV6N2UxNlZHbFlaU1ZpT0lXbkI3V1lPTFIwcmdqOTFaT0dBa0RqZjFDRkxWZjBtMXp5eXdibkRYd2Y3WkNLVDg1U201TS1JLWs4VlRXY2FnU2RudkJmZ1NXcFptOEZYUWZXNjdoZ0p2SDBuOUFqVTU0R09aMFZQb3JDVEZycmF2WmtTT2xwSkNNUXpW?oc=5","date":"2024-10-22","type":"pipeline","source":"GlobeNewswire","summary":"Ocuphire Pharma Announces Acquisition of Opus Genetics - GlobeNewswire","headline":"Ocuphire Pharma Announces Acquisition of Opus Genetics","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_3":3},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":0,"period":"2013-12-31"},{"value":0,"period":"2012-12-31"},{"value":0,"period":"2011-12-31"},{"value":0,"period":"2010-12-31"},{"value":0,"period":"2009-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5476776,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-49591000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":45091000,"cashHistory":[],"totalAssets":50243000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}